Wealthcome
Seed Round in 2023
Wealthcome is a technology company specializing in wealth management solutions. It has developed a comprehensive platform that enables users to monitor, analyze, and optimize their assets, including bank accounts, investments, and real estate. The platform offers tools for expense tracking, fee optimization, and investment performance analysis, empowering clients to take control of their financial portfolios.
Nurea develops AI-powered medical imaging software that transforms standard 2D scans into 3D reconstructions of arterial systems, enabling early detection of cardiovascular and neurovascular conditions such as aneurysms. The solution automates quantitative image analysis, providing accurate, operator-independent assessments that integrate seamlessly into hospital workflows. By allowing clinicians to monitor structural changes over time, the platform supports precise and reliable diagnoses for vascular surgeons and other healthcare professionals.
VISME rehabilitation service.
Medical service providing new opportunities for rehabilitation.
They work at the junction of neurobiology and machine learning. They use computer vision technologies to automatize the methods of rehabilitation.
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.
Ascendis Pharma
Series A in 2007
Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.
NXN Software
Series C in 2001
NXN Software is supplier of Digital Asset and Production Management solutions for the computer graphics and digital entertainment industries.